Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy.

SS-31 treatment in diabetic mice significantly reduced proteinuria, oxidative DNA damage, renal fibrosis markers, and apoptosis in kidney cells. It inhibited key oxidative stress pathways including NADPH oxidase activity and restored mitochondrial function in mouse mesangial cells exposed to high glucose.

The study used diabetic CD-1 mice subjected to uninephrectomy and streptozotocin to induce diabetic nephropathy, followed by daily intraperitoneal injections of SS-31 for 8 weeks. In vitro experiments were conducted on mouse mesangial cells exposed to high-glucose conditions to assess SS-31's effects on oxidative stress and apoptosis.

This research highlights SS-31 as a promising mitochondria-targeted antioxidant peptide that can protect against diabetic kidney injury, a major complication of diabetes. Understanding its mechanism may guide development of new therapies to prevent or treat diabetic nephropathy.

The study was conducted in a mouse model and cultured cells, so results may not fully translate to humans. The exact clinical efficacy and safety of SS-31 in diabetic patients remain to be established.